In Vitro Evaluation of Pro- and Anticoagulant Drugs in Children with End-Stage Liver Disease Undergoing Liver Transplantation

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)

Abstract

Background âPro- A nd anticoagulant drugs are commonly used in pediatric liver transplantation to prevent and treat thrombotic and bleeding complications. However, the combination of baseline hemostatic changes in children with liver disease and additional changes induced by transplantation makes this very challenging. This study aimed to analyze the efficacy of clinically available pro- A nd anticoagulant drugs in plasma from children undergoing liver transplantation. Methods âIn vitro effects of pro- A nd anticoagulant drugs on thrombin generation capacity were tested in plasma samples of 20 children (≤ 16 years) with end-stage liver disease undergoing liver transplantation, and compared with 30 age-matched healthy controls. Results âAddition of pooled normal plasma had no effect in patients or controls, while 4-factor prothrombin complex concentrate increased thrombin generation in both patients and controls, with enhanced activity in patients. At start of transplantation, dabigatran and unfractionated heparin had a higher anticoagulant potency in patients, whereas 30 days after transplantation low molecular weight heparin was slightly less effective in patients. Effects of rivaroxaban were comparable between patients and controls. Conclusion âThis study revealed important differences in efficacy of commonly used pro- A nd anticoagulant drugs in children with end-stage liver disease undergoing liver transplantation. Therefore, dose adjustments of these drugs may be required. The results of this study may be helpful in the development of urgently needed protocols for strategies to prevent and treat bleeding and thrombotic complications in pediatric liver transplantation.

Original languageEnglish
Pages (from-to)1240-1247
Number of pages8
JournalThrombosis and Haemostasis
Volume120
Issue number09
Early online date6-Jul-2020
DOIs
Publication statusPublished - Sep-2020

Keywords

  • coagulation
  • hemostasis
  • liver transplantation
  • pro
  • and anticoagulant drugs
  • thrombosis
  • HEMOSTASIS
  • COAGULATION
  • MANAGEMENT
  • PLASMA
  • COMPLICATIONS
  • COAGULOPATHY
  • DABIGATRAN
  • THROMBOSIS
  • THERAPY

Cite this